KL and chronic kidney disease: These results collectively indicate that SAMP1/kl-/- mice may represent a relevant model for investigating the pathogenic mechanisms underlying aging and that HL156A is a potential preclinical therapeutic modality for treating renal disease, including acute kidney disease (AKD) and early chronic kidney disease (CKD).